GINI-HEALTH
1.10.2021 11:58:04 CEST | Business Wire | Press release
Gini Health, one of North America's fastest growing health-tech companies, has teamed up with world-class doctors to launch a type 2 diabetes reversal program. Riding on the success of its pilot 12-week diabetes reversal program, conducted with participants from South Asian diaspora, Gini Health today announced that it has debuted into chronic health care management.
Data from Gini Health’s 12 week pilot program provided promising evidence that type 2 diabetes can be reversed by making appropriate lifestyle changes. The results showed that 65% of participants enrolled in Gini Health’s diabetes reversal program achieved below 6.5 HBA1c levels, 4-12% weight loss and 40% participants reduced blood pressure while also witnessing improvements in other biomarkers. The program was also successful in reducing insulin injections and diabetes-specific prescriptions medications for 92% of its participants, in just 12 weeks.
Gini's diabetes program is a doctor-led continuous care program customized for each patient using the latest global research and participant's health data. Gini's care team provides daily coaching and support to participants. Gini health’s mobile app records glucose data from continuous glucose monitoring devices along with data from other devices like weight, activity, sleep, blood pressure and food intake. Gini doctors use this data to adjust patient's diet, lifestyle and medication to get the best results continuously.
Managing diabetes is extremely complex and people with diabetes face a hard task of doing it alone with very few doctor visits in a year. They struggle with monitoring and keeping in control their blood sugar levels with diet and medication and at the same time managing associated conditions like high blood pressure. Therefore making a doctor-led program using data and technology was key for Gini Health, if they were going to serve hundreds of millions of people with diabetes globally.
With their continuous care model, they support patients at every step of their remission journey. Gini’s team has top medical experts, including doctors, researchers, nutritionists and care specialists that help their customers achieve their health goals.
"Globally, there is a big gap in the diabetes care model that can be filled with our approach of bringing evidence based research, and combining technology with best doctors. Our pilot program’s success is a great start to make it available to more people." said Gurjot Narwal, Founder & CEO of Gini Health.
About Gini Health
Gini Health is a Canada based health-tech company that serves customers across North America and Europe. Gini Health has received various awards and accolades for its personalized healthcare approach in preventive health care. Gini was invested by global VCs like TechStars, Rangle, Uken among others. It has grown into a digital healthcare services company with the launch of its first chronic health care management program.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005294/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
